Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christiana Smith

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Clinical Microbiology|October 23, 2020
Comparison of Upper Respiratory Viral Load Distributions in Asymptomatic and Symptomatic Children Diagnosed with SARS-CoV-2 Infection in Pediatric Hospital Testing ProgramsLarry K Kociolek, William J Muller, Rebecca Yee, et al.
The Lancet. HIV|January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trialElizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV|January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm studyAditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Lancet. HIV|March 27, 2024
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyAditya H Gaur, Edmund V Capparelli, Katherine Calabrese, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
The Emergence of Zoonotic Onchocerca lupi Infection in the United States--A Case-SeriesPaul T Cantey, Jessica Weeks, Morven Edwards, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Clinical Microbiology|October 23, 2020
Comparison of Upper Respiratory Viral Load Distributions in Asymptomatic and Symptomatic Children Diagnosed with SARS-CoV-2 Infection in Pediatric Hospital Testing ProgramsLarry K Kociolek, William J Muller, Rebecca Yee, et al.
The Lancet. HIV|January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trialElizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV|January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm studyAditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Lancet. HIV|March 27, 2024
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyAditya H Gaur, Edmund V Capparelli, Katherine Calabrese, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
The Emergence of Zoonotic Onchocerca lupi Infection in the United States--A Case-SeriesPaul T Cantey, Jessica Weeks, Morven Edwards, et al.
Pageof 4